第一年:在全民医疗体系中为所有高级别浆液性卵巢癌实施反射性BRCA1和BRCA2肿瘤检测后三级癌症中心的经验
该回顾性图表综述比较了全民医疗体系中实施反射性BRCA1/2肿瘤检测前后高级别浆液性卵巢癌(HGSOC)患者的遗传转诊率、转诊时间及遗传服务接受度。实施后遗传转诊率升高(12.88 vs 7.10/1000人日;IRR=1.60,95%CI:1.07-2.42),中位转诊时间缩短(59天 vs 33天;p=.04),而遗传咨询和胚系检测接受度无显著差异。结论认为反射性检测显著改善了转诊率和转诊时间,需进一步研究评估医生转诊实践和长期影响。
要点
- 实施反射性BRCA1/2肿瘤检测后,HGSOC患者遗传转诊率升高(IRR=1.60,95%CI:1.07-2.42)。
- 实施后中位转诊时间从59天缩短至33天(p=.04)。
- 转诊后遗传咨询和胚系检测接受度在实施前后无显著差异。
核心结论
- 实施反射性BRCA1/2肿瘤检测后,HGSOC患者的遗传转诊率和转诊时间均得到显著改善。
- 需要额外研究评估医生转诊实践和反射性肿瘤检测的长期影响。
研究设计与样本
- 回顾性图表综述,纳入实施反射性BRCA1/2肿瘤检测前一年(PRE)和后一年(POST)诊断的HGSOC患者,共175例(PRE组81例;POST组94例)。
- 计算发病率比(IRR)和95%CI采用负二项回归;转诊时间采用Kaplan-Meier生存分析;遗传服务接受度采用Fisher精确检验。
主要发现
- POST组遗传转诊率高于PRE组(12.88 vs 7.10/1000人日;IRR=1.60,95%CI:1.07-2.42)。
- POST组从诊断到转诊的中位时间短于PRE组(33天 vs 59天;p=.04)。
- POST队列中多数患者在收到肿瘤结果前即被转诊(63/77;81.8%)。
- 转诊后遗传咨询出席率PRE组为94.5%、POST组为97.6%(p=.418),无显著差异。
- 转诊后进行胚系检测的比例PRE组为98.6%、POST组为100%(p=.455),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study compares the rate and time to genetic referral, and patient uptake of germline genetic services, before and after implementation of reflex BRCA1/2 tumor testing for high-grade serous ovarian cancer (HGSOC) in a universal healthcare system. METHODS: A retrospective chart review of HSGOC patients diagnosed in the year before (PRE) and after (POST) implementation of reflex BRCA1/2 tumor testing was conducted. Clinical information (date/age at diagnosis, personal/family history of breast/ovarian cancer, cancer stage, primary treatment, tumor results) and dates of genetics referral, counseling, and germline testing were obtained. Incident rate ratios (IRR) and 95% CI were calculated using negative binomial regression. Time to referral was evaluated using Kaplan-Meier survival analysis. Fisher Exact tests were used to evaluate uptake of genetic services. RESULTS: 175 HGSOC patients were identified (81 PRE; 94 POST). Post-implementation of tumor testing, there was a higher rate of genetics referral (12.88 versus 7.10/1000 person-days; IRR = 1.60, 95% CI: 1.07-2.42) and a shorter median time from diagnosis to referral (59 days PRE, 33 days POST; p = .04). In the POST cohort, most patients were referred prior to receiving their tumor results (n = 63/77; 81.8%). Once referred, most patients attended genetic counseling (94.5% PRE, 97.6% POST; p = .418) and pursue germline testing (98.6% PRE; 100% POST; p = .455). CONCLUSIONS: Following implementation of reflex BRCA1/2 tumor testing for HGSOC, significant improvements to the rate and time to genetics referral were identified. Additional studies are needed to evaluate physician referral practices and the long-term impact of reflex tumor testing.
引用
- McCuaig JM, Care M, Ferguson SE, et al. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecol Oncol. 2020. PMID: 32674931. doi:10.1016/j.ygyno.2020.06.507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。